At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
High-Flow, 20 LPM (via Optiflow cannula) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis
In Brief
A clinical study evaluating High-Flow, 20 LPM (via Optiflow cannula) and Low FLow, 5 LPM (via Optiflow cannula) for Cystic Fibrosis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study is a single center, randomized pilot study to evaluate the clinical effectiveness of nasal high flow 20LPM humidification therapy in subjects with Cystic Fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartMay 2015
Primary CompletionMay 2019
TodayJul 2026
First PostedMay 2, 2014
Enrollment StartMay 1, 2015
Primary CompletionMay 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.2 years ago
Interventions
High-Flow, 20 LPM (via Optiflow cannula)device
Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
Low FLow, 5 LPM (via Optiflow cannula)device
standard humidified wall medical air.